Visionary Therapeutics

Headlines

Charlesson selected to recieve two-year funding from Oklahoma EDGE

Charlesson Senior Vice-President, Dr. Mostafa Analoui, to speak at the 21st Century Medicine: Breakthroughs and Challenges Conference

Charlesson Senior Vice-President, Dr. Mostafa Analoui, to speak at the 13th Annual Drug Delivery Partenrships meeting

Charlesson Senior Vice-President, Dr. Mostafa Analoui, to speak at the 13th Annual World Congress of Drug Discovery and Development of Innovative Therapeutics

Charlesson scientist,
Dr. Rafal Farjo, receives $241,000 Phase I SBIR grant from the National Institutes of Health to develop CLT-005 for
Retinal Inflammation and Neovascularization

OUR MISSION

Charlesson is actively engaged in the development of therapeutics for treating numerous human diseases. Our product pipeline includes pharmaceutical treatments for Age-Related Macular Degeneration, Diabetic Retinopathy, Ocular Inflammation, Angiogenesis, and systemic diabetes.

For more information on our drug discovery pipeline, please click below	For more information on our preclincal service offerings, please click below

This website is best viewed with Internet Explorer